| Name | Staurosporine |
| Description | Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis. |
| Cell Research | Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined. (Only for Reference) |
| Kinase Assay | Enzyme assay and binding assay: Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine. |
| In vitro | METHODS: Human cervical cancer cells HeLa were treated with Staurosporine (1-10 nM) for 72 h, and cell viability was measured by MTT.
RESULTS: Staurosporine inhibited the proliferation of Hela cells in a dose-dependent manner, with an IC50 of about 10 nM. [1]
METHODS: Human pancreatic cancer cells PaTu 8988t and Panc-1 were treated with Staurosporine (1 μM) for 3-24 h, and cell death was detected by Flow Cytometry.
RESULTS: For PaTu 8988t cells, incubation with Staurosporine for 3-24 h significantly increased apoptosis and significantly decreased the number of viable cells; necrosis increased after 6-16 h. For Panc-1 cells, Staurosporine treatment significantly increased apoptosis and significantly decreased the number of viable cells after 9-24 h. The RESULTS were summarized as follows. [2]
METHODS: Human hepatocellular carcinoma cells HepG2 were treated with Staurosporine (20 nmol/L) for 6-24 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: Staurosporine significantly inhibited the phosphorylation of mTOR and increased the expression of LC3-II, an autophagy marker protein, suggesting that Staurosporine activates autophagy effectively by inhibiting mTOR. [3] |
| In vivo | METHODS: To assay anti-tumor activity in vivo, Staurosporine (3 mg/kg) and Lapatinib (50 mg/kg) were administered by gavage twice a week for two weeks to Nu/J-Foxn1 Nu/Nu mice harboring human mammary carcinoma tumors JIMT-1.
RESULTS: The combination of Staurosporine and Lapatinib inhibited tumor growth in a statistically significant manner. [4]
METHODS: To examine the effects on islet β-cell function, Staurosporine (0.4 mg/kg in 0.5% sodium carboxymethyl cellulose) was administered intraperitoneally to iPLA2β-/- C57BL6 mice once daily for two weeks. for two weeks.
RESULTS: Staurosporine impairs glucose tolerance and glucose-stimulated insulin secretion in pancreatic islets. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble)
DMSO : 13.75 mg/mL (29.47 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.1 mg/mL (6.64 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
|
| Keywords | Antibiotic | Apoptosis | PKC | Protein kinase A | Staurosporine | Antibiotic AM2282 | Antibiotic AM 2282 | Bacterial | Protein kinase C | AM 2282 | inhibit | Inhibitor | Fungal | STS | CGP-41251 | PKA | AM2282 | CGP41251 |
| Inhibitors Related | Neomycin sulfate | Stavudine | Dehydroacetic acid sodium | Ampicillin sodium | Dextran sulfate sodium salt (MW 4500-5500) | Kanamycin sulfate | Sodium 4-phenylbutyrate | Sulfamethoxazole sodium | Doxycycline | Tributyrin | Dimethyl sulfoxide | Oleic acid |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Alkaloid Natural Product Library | Rare Natural Product Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-infective Natural Product Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library |
United States
